Tailoring haemophilia A prophylaxis with BAY 81-8973: A case series

Sergio Siragusa, Mariasanta Napolitano, Gaetano Giuffrida, Valeria Calafiore, Rita Carlotta Santoro, Fabio Gagliano, Filomena Daniele, Rita Carlotta Santoro, Maria Francesca Mansueto

Risultato della ricerca: Articlepeer review

2 Citazioni (Scopus)


BAY 81-8973 is an unmodified, full-length third generation recombinant factor VIII (rFVIII) which offers a more favorable pharmacokinetic (PK) profile, compared to its predecessor sucrose-formulated rFVIII (rFVIII-FS). We here report on a retrospective case series of nine patients affected by hemophilia A (HA), with variable disease severity, bleeding phenotype and comorbidities, to underline our clinical practice on prophylaxis with a recently introduced standard hall-life recombinant Factor VIII. The current case series highlights how the current clinical management of hemophilia is able to personalize treatment in several specific conditions like concomitant illnesses with thrombotic risk and allergic reactions.
Lingua originaleEnglish
pagine (da-a)102897-
Numero di pagine6
RivistaTransfusion and Apheresis Science
Stato di pubblicazionePublished - 2020

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2700.2720???


Entra nei temi di ricerca di 'Tailoring haemophilia A prophylaxis with BAY 81-8973: A case series'. Insieme formano una fingerprint unica.

Cita questo